For U.S. Healthcare Professionals

Dosing
& Administration

Consistent &
Predictable
Dosing¹

For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.

SIMPLE DOSING FOR YOUR PATIENTS WITH UC OR CD¹

Entyvio offers your patients consistent, predictable dosing¹

MOVE AHEAD TO

Starting & Maintaining
Treatment

Dosing & Administration
Information

Dosing & Administration
Video

STARTING & MAINTAINING TREATMENT

HOW TO START

Start with infusions at Weeks 0, 2, and 6

HOW TO MAINTAIN

Continue every 8 weeks thereafter

Discontinue therapy in patients who show no
evidence of therapeutic benefit by Week 14

After 1 year, a patient will receive 6 maintenance doses per year, with a total annual infusion time of approximately 3 hours.¹

DOSING & ADMINISTRATION INFORMATION

ADMINISTRATION

Administered as a 300 mg flat dose over an approximately 30‑minute IV infusion¹
A total of 6 maintenance doses annually after the first year¹
Do not administer as an IV push or bolus

MONITORING

Entyvio IV should be administered by a healthcare professional prepared to manage hypersensitivity reactions, including anaphylaxis, if they occur. Appropriate monitoring and medical support measures should be available for immediate use. Observe patients during infusion and until the infusion is complete¹

CONCOMITANT THERAPIES

Entyvio can be administered concomitantly with aminosalicylates, steroids, or immunomodulators¹

PRIOR TO ADMINISTRATION

Patients should be brought up to date with all immunizations prior to starting Entyvio¹

For complete dosage and administration information, please see full Prescribing Information.

Starting and Maintaining Treatment

DOSING & ADMINISTRATION VIDEO

For demonstrative purposes only.
Please see full Prescribing Information for complete reconstitution and dilution instructions.

Get your patients started with
EntyvioConnect

LEARN MORE

Find helpful resources
for your practice & your patients

FIND OUT MORE

Important Safety Information

ENTYVIO (vedolizumab) for injection is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Infusion-related reactions and hypersensitivity reactions including anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, rash, and increased blood pressure and heart rate have been reported. These reactions may occur with the first or subsequent infusions and may vary in their time of onset from during infusion or up to several hours post-infusion. If anaphylaxis or other serious infusion-related or hypersensitivity reactions occur, discontinue administration of ENTYVIO immediately and initiate appropriate treatment.
Patients treated with ENTYVIO are at increased risk for developing infections. Serious infections have been reported in patients treated with ENTYVIO, including anal abscess, sepsis (some fatal), tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, and cytomegaloviral colitis. ENTYVIO is not recommended in patients with active, severe infections until the infections are controlled. Consider withholding ENTYVIO in patients who develop a severe infection while on treatment with ENTYVIO. Exercise caution in patients with a history of recurring severe infections. Consider screening for tuberculosis (TB) according to the local practice.
Progressive multifocal leukoencephalopathy (PML), a rare and often fatal opportunistic infection of the central nervous system (CNS), has been reported with systemic immunosuppressants, including another integrin receptor antagonist. PML is caused by the John Cunningham (JC) virus and typically only occurs in patients who are immunocompromised. One case of PML in an ENTYVIO-treated patient with multiple contributory factors has been reported in the postmarketing setting (e.g., human immunodeficiency virus [HIV] infection with a CD4 count of 300 cells/mm³ and prior and concomitant immunosuppression). Although unlikely, a risk of PML cannot be ruled out. Monitor patients for any new or worsening neurological signs or symptoms. Typical signs and symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. If PML is suspected, withhold dosing with ENTYVIO and refer to a neurologist; if confirmed, discontinue ENTYVIO dosing permanently.
There have been reports of elevations of transaminase and/or bilirubin in patients receiving ENTYVIO. ENTYVIO should be discontinued in patients with jaundice or other evidence of significant liver injury.
Prior to initiating treatment with ENTYVIO, all patients should be brought up to date with all immunizations according to current immunization guidelines. Patients receiving ENTYVIO may receive non-live vaccines and may receive live vaccines if the benefits outweigh the risks.
Most common adverse reactions (incidence ≥3% and ≥1% higher than placebo): nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities.

Please see full Prescribing Information, including Medication Guide.

Indications

Adult Ulcerative Colitis (UC)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active UC.

Adult Crohn's Disease (CD)

ENTYVIO (vedolizumab) is indicated in adults for the treatment of moderately to severely active CD.

ENTYVIO is available for injection: 300 mg vedolizumab.

Please see full Prescribing Information, including Medication Guide.

Reference:

Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.

Dosing & Administration

Consistent & Predictable Dosing1